Lipid composition and cholesterol nucleation time in gallbladder bile of patients with cholesterol gallstones under choleretic treatment with Febuprol.
The effect of a new potent choleretic drug (Febuprol) on lipid composition and cholesterol nucleation time in gallbladder bile was studied in 8 patients with cholesterol gallstones. Nine untreated patients with cholesterol cholecystolithiasis and functioning gallbladder served as controls. Under Febuprol treatment (3 X 100 mg for 6-10 days) mean concentrations of total bile acids (125.4 vs. 59.5 mmol/l), phospholipids (46.1 vs. 25.6 mmol/l) and total lipids (10.4 vs. 5.9 g/dl) were significantly higher (p less than 0.01) than in controls. No significant difference between both groups was calculated for the mean values of cholesterol (17.8 vs. 13.3 mmol/l), cholesterol saturation index (1.5 vs. 2.1) and cholesterol nucleation time (2.1 vs. 2.6 days). Our findings are compatible with a choleretic effect of Febuprol but no alteration of the rapid cholesterol crystallisation in gallbladder bile of patients with cholesterol gallstones was found.
Jüngst
D
D
Department of Medicine II and Surgery, University of Munich.
Brenner
G
G
Pratschke
E
E
Paumgartner
G
G
D000433:1-Propanol / Q000627:therapeutic use; D001646:Bile / Q000187:drug effects* / Q000378:metabolism; D002756:Cholagogues and Choleretics / Q000627:therapeutic use*; D002763:Cholecystectomy; D002769:Cholelithiasis / Q000188:drug therapy* / Q000378:metabolism; D002784:Cholesterol / Q000378:metabolism*; D003131:Combined Modality Therapy; D006801:Humans; D050356:Lipid Metabolism; D008875:Middle Aged; D010647:Phenyl Ethers; D020005:Propanols
D002756:Cholagogues and Choleretics; D010647:Phenyl Ethers; D020005:Propanols; D000433:1-Propanol; D002784:Cholesterol; C006281:febuprol